Roth Capital Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
UBS Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Sell
October 7, 2014 7:27 AM EDTUBS downgraded Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) from Neutral to Sell with a price target of $1.50.
For an analyst ratings summary and ratings history on Sunesis Pharmaceuticals Inc. click here. For more ratings news on Sunesis Pharmaceuticals Inc. click here.
Shares of Sunesis Pharmaceuticals Inc. closed at $1.46 yesterday.
... MoreCantor Fitzgerald Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Hold
October 7, 2014 7:12 AM EDTCantor Fitzgerald downgraded Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) from Buy to Hold with a price target of $2.00.
For an analyst ratings summary and ratings history on Sunesis Pharmaceuticals Inc. click here. For more ratings news on Sunesis Pharmaceuticals Inc. click here.
Shares of Sunesis Pharmaceuticals Inc. closed at $1.46 yesterday.
... MoreSunesis Pharmaceuticals (SNSS) Reports Phase 3 VALOR Missed Primary Endpoint
October 6, 2014 6:33 AM EDTSunesis Pharmaceuticals (Nasdaq: SNSS) announced results from the pivotal Phase 3 VALOR trial, a randomized, double-blind, placebo-controlled trial of vosaroxin and cytarabine in patients with first relapsed or refractory acute myeloid leukemia (AML). At more than 100 leading international sites, the trial enrolled 711 patients, who were stratified for age, geography and disease status. The trial did not meet its primary endpoint of demonstrating a statistically significant improvement in overall survival, with a median overall survival of 7.5 months for vosaroxin and cytarabine compared to 6.1 months for placebo and cytarabine (HR=0.865, p=0.06). Because transplant may confound the primary... More
